These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results. Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946 [TBL] [Abstract][Full Text] [Related]
24. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Connett GJ Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974 [TBL] [Abstract][Full Text] [Related]
25. Short communication: novel truncating mutations in the CFTR gene causing a severe form of cystic fibrosis in Italian patients. Lenarduzzi S; Morgutti M; Crovella S; Coiana A; Rosatelli MC Genet Mol Res; 2014 Nov; 13(4):9636-41. PubMed ID: 25501174 [TBL] [Abstract][Full Text] [Related]
26. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis. Bergougnoux A; Petit A; Knabe L; Bribes E; Chiron R; De Sario A; Claustres M; Molinari N; Vachier I; Taulan-Cadars M; Bourdin A Int J Biochem Cell Biol; 2017 Jul; 88():124-132. PubMed ID: 28478266 [TBL] [Abstract][Full Text] [Related]
27. A Rare Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation Associated With Typical Cystic Fibrosis in an Arab Child. Mathew A; Dirawi M; Abou Tayoun A; Popatia R Cureus; 2021 Feb; 13(2):e13526. PubMed ID: 33786233 [TBL] [Abstract][Full Text] [Related]
28. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426 [TBL] [Abstract][Full Text] [Related]
33. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation. Dilokthornsakul P; Patidar M; Campbell JD Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892 [TBL] [Abstract][Full Text] [Related]
34. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
35. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391 [TBL] [Abstract][Full Text] [Related]
36. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. Alibakhshi R; Kianishirazi R; Cassiman JJ; Zamani M; Cuppens H J Cyst Fibros; 2008 Mar; 7(2):102-9. PubMed ID: 17662673 [TBL] [Abstract][Full Text] [Related]
37. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency. AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis. Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331 [TBL] [Abstract][Full Text] [Related]
39. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Mickle JE; Cutting GR Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548 [TBL] [Abstract][Full Text] [Related]
40. Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN. Merkert S; Bednarski C; Göhring G; Cathomen T; Martin U Stem Cell Res; 2017 Aug; 23():95-97. PubMed ID: 28925369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]